Recent reports have suggested that opioid peptides may be involved in renal water excretion. The present in vivo experiments, therefore, were undertaken to determine the effect of opioid peptides on the osmotic and nonosmotic release of arginine vasopressin (AVP) in the conscious rat. Experimental animals were infused intravenously with naloxone (20 µg/kg per min) or oxilorphan (40 µg/kg per min), chemically dissimilar opioid antagonists. Control rats were infused with normal saline, the vehicle for the opioid antagonists. In all three groups the osmotic release of AVP was examined during an acute hypertonic saline (3%) infusion (2 ml/100 g body wt). The antidiuresis following the hypertonic saline infusion was significantly attenuated in naloxone-and oxilorphan-treated rats, as the peak urinary osmolality (Uosm) rose to 581.4±22.4 and 558.2±27.6 mosmol/kg H 2 O in naloxone-and oxilorphan-treated rats as compared with the value in control rats of 735.3±24.2 mosmol/kg H 2 O (both P < 0.001 vs. control). At the same time the plasma AVP levels of 5.4±1.3 and 5.2±1.1 pg/ml in naloxone-and oxilorphan-treated rats, respectively, were significantly lower than the plasma AVP in control rats of 16.9±2.5 pg/ml (P < 0.001). In another three groups of rats the nonosmotic release of AVP was examined during hypovolemia induced by intraperitoneal 6% dextran (1.8 ml/100 g body wt min), chemically dissimilar opioid antagonists. Control rats were infused with normal saline, the vehicle for the opioid antagonists. In all three groups the osmotic release of AVP was examined during an acute hypertonic saline (3%) infusion (2 ml/100 g body wt). The antidiuresis following the hypertonic saline infusion was significantly attenuated in naloxone-and oxilorphan-treated rats, as the peak urinary osmolality (Uosm) rose to 581.4±22.4 and 558.2±27.6 mosmol/ kg H20 in naloxone-and oxilorphan-treated rats as compared with the value in control rats of 735.3±24.2 mosmol/kg H20 (both P < 0.001 vs. control). At the same time the plasma AVP levels of 5.4±1.3 and 5.2±1.1 pg/ml in naloxone-and oxilorphan-treated rats, respectively, were significantly lower than the plasma AVP in control rats of 16.9±2.5 pg/ml (P < 0.001). In another three groups of rats the nonosmotic release of AVP was examined during hypovolemia induced by intraperitoneal 6% dextran (1.8 ml/ 100 g body wt). Following intraperitoneal administration of dextran the peak Uosm of 703.0±87.8 and 734.8±99.1 mosmol/kg H20 in naloxone-and oxilorphan-treated rats, respectively, was significantly less than the value in control rats of 1,169.3±135.5 mosmol/kg H20 (both P < 0.02 vs. control). A comparable decrease in blood volume of 13% occurred in all three groups of animals. During the dextran administration plasma AVP levels in naloxone-and oxilorphan-treated rats increased to 4.3±1.0 and 6.0±2.0 pg/ml, respectively; both of these values were signifAddress reprint requests to Dr. Schrier.
A B S T R A C T Recent reports have suggested that opioid peptides may be involved in renal water excretion. The present in vivo experiments, therefore, were undertaken to determine the effect of opioid peptides on the osmotic and nonosmotic release of arginine vasopressin (AVP) in the conscious rat. Experimental animals were infused intravenously with naloxone (20 ,g/kg per min) or oxilorphan (40 ,g/kg per min), chemically dissimilar opioid antagonists. Control rats were infused with normal saline, the vehicle for the opioid antagonists. In all three groups the osmotic release of AVP was examined during an acute hypertonic saline (3%) infusion (2 ml/100 g body wt). The antidiuresis following the hypertonic saline infusion was significantly attenuated in naloxone-and oxilorphan-treated rats, as the peak urinary osmolality (Uosm) rose to 581.4±22.4 and 558.2±27.6 mosmol/ kg H20 in naloxone-and oxilorphan-treated rats as compared with the value in control rats of 735.3±24.2 mosmol/kg H20 (both P < 0.001 vs. control). At the same time the plasma AVP levels of 5.4±1.3 and 5.2±1.1 pg/ml in naloxone-and oxilorphan-treated rats, respectively, were significantly lower than the plasma AVP in control rats of 16.9±2.5 pg/ml (P < 0.001). In another three groups of rats the nonosmotic release of AVP was examined during hypovolemia induced by intraperitoneal 6% dextran (1.8 ml/ 100 g body wt). Following intraperitoneal administration of dextran the peak Uosm of 703.0±87.8 and 734.8±99.1 mosmol/kg H20 in naloxone-and oxilorphan-treated rats, respectively, was significantly less than the value in control rats of 1,169.3±135.5 mosmol/kg H20 (both P < 0.02 vs. control). A comparable decrease in blood volume of 13% occurred in all three groups of animals. During the dextran administration plasma AVP levels in naloxone-and oxilorphan-treated rats increased to 4.3±1.0 and 6.0±2.0 pg/ml, respectively; both of these values were signif- INTRODUCTION Opioid peptides are derived from a common precursor, ,3-lipotropin (1) , and the genetic sequencing of opioid peptides is determined by the sequence of ACTH-f3-lipotropin (2, 3) . These opioid peptides are distributed in various tissues that originated from ectoderm; thus, the hypothalamus and pituitary gland are areas of high opioid content as measured by radioimmunoassay techniques (4) . The opioid peptides are divided into two groups, namely the endorphins and enkephalins. In the pituitary gland the endorphins are localized mainly in the adenohypophysis and pars intermedia, while the enkephalins are localized mainly in the neurohypophysis. Since there are also opioid receptors with high affinity binding properties in the neurohypophysis (5), it is reasonable to suggest that enkephalins may be involved in the release of arginine vasopressin (AVP)' from the neurohypophysis.
The first study that examined the antidiuretic effect of morphine was reported by DeBodo in 1944 (6) and, more recently, several additional studies have reexamined the role of opiates and opiate antagonists (6) (7) (8) (9) (10) (11) and opioid peptides (12) (13) (14) (15) (16) (17) in renal water excretion. Taken together, these studies have not yielded consistent results. Specifically, opiates and opioid peptides have been suggested both to stimulate (6) (7) (8) (9) (10) (11) (12) (13) 17) and to inhibit AVP release (14) (15) (16) Another group of equally treated experimental and control rats received the hypertonic saline and had plasma AVP concentrations measured. Since the peak Uosm after the infusion of hypertonic saline was found to occur between 18 and 23 min in our earlier experiments (18) , a 2.0-ml blood sample was taken rapidly over 10 s through the carotid artery catheter exactly 20 min after commencing the infusion of hypertonic saline. The water-diuresing rats were prepared in the same manner as all other animals. In these animals plasma AVP samples were drawn after a water diuresis was established (Uosm < 150 mosmol/kg H20). We have previously established that blood removal over 10 s does not stimulate AVP release rapidly enough to effect the AVP content in the withdrawn blood specimen (18) .
Hyperoncotic dextran protocol. The intraperitoneal administration of 6% of dextran T-70 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) was used as a nonosmotic, hypovolemic stimulus for AVP release. Rats used in this experiment were prepared in the same manner as described above, with the exception of placement of an intraperitoneal catheter (PE-350, Clay-Adams) at the time of surgery. After establishing a water diuresis, control collections of blood and urine samples were obtained, followed by the infusion of naloxone, oxilorphan or the vehicle as described in the hypertonic saline protocol. The animals were then given an intraperitoneal injection of dextran (1.8 ml/100 g body wt) at a rate of 1 ml/min. The estimated oncotic pressure of this solution (van't Hoff equation) is 800 mm H20. After injection of intraperitoneal dextran, the experimental periods were started and urine was collected at 5-min intervals and blood was taken every 15 min for 90 min. The blood removed was replaced with an equivalent volume of isotonic saline. Estimated changes in blood volume (ABV) were calculated by the formula [ABV = 1 -(Hct 2/Hct 1)]. This method probably underestimates the ABV because it does not account for the erythrocyte volume removed during blood sampling.
In a separate group of experimental and control rats, blood samples were taken for the determination of AVP. Because the peak Uosm after the injection of dextran was found to occur between 30 and 60 min in our earlier experiments, 2.0-ml blood samples were taken rapidly over 10 s through the carotid arterial line exactly 45 min after the start of the experimental periods.
Studies on the effect of opioid antagonists on the renal response to exogenous AVP. To ascertain whether any of the observed changes in Uosm in rats receiving opioid antagonists was due to an alteration in the renal response to AVP, the responses to exogenous AVP were examined. The rats were prepared in the same manner as noted in the previous protocols. After establishing a water diuresis, three 4-min urine collections were obtained. Immediately after these collections, a bolus of 4 ng/kg body wt of AVP (Aqueous Pitressin; Parke-Davis & Co., Detroit, Mich.) was administered. Sequential 4-min urine collections were taken until Uosm returned to 150 mosmol/kg H20 or below. At this time naloxone, oxilorphan, or the vehicle was administered at the same rates as in earlier protocols. 45 min later three 4-min control urine collections were again obtained, and then a second bolus of 4 ng/kg body wt of AVP was administered. Again, urine collections were continued until Uosm decreased to <150 mosmol/kg H20.
In all studies arterial blood pressure was monitored throughout the experiments by a strain gauge ( 
RESULTS
Hypertonic saline study. The Posm during the water diuresis and after administration of opioid antagonists or the vehicle ranged from 287.0 to 291.2 mosmol/kg H20 and was not significantly different among the three groups. The Posm after intravenous administration of hypertonic saline increased significantly by -20 mosmol/kg H20 in all of the three groups of animals (P < 0.001). In all three groups the Uosm during the water diuresis was <150 mosmol/kg H20 as shown in Fig. 1 . After the administration of the opioid antagonists or the vehicle Uosm remained <150 mosmol/kg H20. After the infusion of 3% saline the peak Uosm was signficantly less in the naloxoneand the oxilorphan-treated rats as compared with the control rats. Specifically, peak Usom rose to 581.4±22.4 (n = 7) and 558.2±27.6 mosmol/kg H20 (n = 7) in naloxone-and oxilorphan-treated rats, respectively, and these values were significantly lower than the Uosm in control rats (n = 7) of 735.2±24.2 mosmol/ kg H20 (P < 0.001) (Fig. 1) . As depicted in Table I Fig. 2 . Mean plasma AVP level during the water diuresis was 0.5±0.2 pg/ml (n = 7). In all three groups the plasma AVP levels after the infusion of hypertonic saline were significantly higher than the plasma AVP levels during water diuresis (P < 0.005). Plasma AVP concentrations were 5.4±1.3 pg/ml in the naloxone-treated rats (n = 9), 5.2±1.1 pg/ml in the oxilorphan-treated rats (n = 7), and 16.9±2.5 pg/ml in control rats (n = 10). The increase in plasma AVP in both naloxone-and oxilorphan-treated rats after the infusion of hypertonic saline was significantly less than the AVP concentrations in the control rats (both P <0.001).
Hyperoncotic dextran study. Comparable decreases in blood volume (-13%) occurred in all three groups of rats following the intraperitoneal administration of dextran (P < 0.001). As depicted in Fig. 3 , Uosm during water diuresis was <150 mosmol/kg H20 in all three groups of rats, and remained <150 mosmol/kg H20 after the administration of opioid antagonists or the vehicle. Following the administration of dextran all animals had an antidiuresis in response to the decrease in blood volume. However, the peak Uosm responses in rats receiving opioid antagonists were signficantly blunted when compared to rats receiving vehicle alone (Fig. 3) . Peak Uosm rose to 703.0±87.8 (n = 8) and 734.8±99.1 mosmol/kg H20 (n = 8) in naloxone-and oxilorphan-treated rats, respectively, values that were significantly lower than the control value of 1,169.3±135.5 mosmol/kg H20 (n = 8) (both P < 0.02 vs. control). MAP was slightly but significantly decreased in all three groups of rats after the intraperitoneal administration of dextran (Table II) . Posm and inulin clearance were not significantly different among the three groups of animals (Table II) . UosmV was not signficantly different among the three groups of animals during control periods and after the intraperitoneal administration of dextran. In Fig. 4 are shown the results of decrements in blood volume and plasma AVP levels in the hyperoncotic dextran studies. Plasma AVP levels during water diuresis were 0.6±0.2 pg/ml (n = 7), and 45 min after the intraperitoneal dextran administration plasma AVP levels were significantly increased in all the three groups of rats (P < 0.01). The plasma AVP levels were 4.3±1.0 pg/ml in the naloxone-treated rats (n = 9), 6 .0±2.0 pg/ml in the oxilorphan-treated rats (n = 7), and 12.9± 1.4 pg/ml in the control rats (n = 7). During hyperoncotic dextran administration the values of plasma AVP in both naloxone-and oxilorphan-treated rats were significantly lower than the values in the control group receiving the vehicle (P < 0.001 and P < 0.02, respectively). Effect of opioid antagonists on the renal response to exogenous AVP. In the control group of rats (n = 6), Uosm was increased from 112.3±3.3 to 510.8±27.0 mosmol/kg H20 (P < 0.001) by the first bolus of AVP, and then decreased to 133.0±2.9 mosmol/kg H20 (P < 0.001). During vehicle administration Uosm was increased from 134.3±11.1 to 533.0±31.3 mosmol/kg H20 (P < 0.001) by the second bolus of AVP, which then decreased to 130.3±8.3 mosmol/kg H20 (P < 0.001). In the naloxone group of rats (n = 6), the first bolus of AVP increased Uosm from 115.8±10.2 to 579.6±78.8 mosmol/kg H20 (P < 0.001), and Uosm Water Opioid Antagonists Hyperoncotic Increment in Posm (mosmol/kg H20) returned to 123.2±12.9 mosmol/kg H20 (P < 0.001) after the effect of the hormone dissipated. After naloxone administration, Uosm was 127.0±12.7 mosmol/ kg H20 and the second bolus of AVP increased Uosm to 554.8±45.4 mosmol/kg H20 (P < 0.001), which then decreased to 141.3±4.6 mosmol/kg H20 (P < 0.001).
In the oxilorphan group of rats (n = 6), Uosm increased from 108.2±15.5 to 504.0±76.4 mosmol/kg H20 (P < 0.001) after the first bolus of AVP and then fell to 123.3±9.0 mosmol/kg H2O (P < 0.001). After oxilorphan administration a second bolus of AVP increased Uosm from 120.8±8.6 to 510.5±55.2 mosmol/kg H20 (P < 0.001), which then returned to 142.3±5.0 mosmol/kg H20 (P < 0.001). In all three groups of rats the response of peak Uosm to exogenous AVP was not significantly different during any phase of the experiments. Similar studies were performed using 1 ng/kg rather than 4 ng/kg of AVP. Once again no end-organ effect of opioid antagonist on the renal response to (28, 30) . There is no ready explanation for these latter differences. It should be emphasized, however, that the present studies were performed in conscious rats, using a sensitive radioimmunoassay for AVP, two chemically dissimilar opioid antagonists and both osmotic and nonosmotic release of AVP were examined.
Since the nonosmotic (baroreceptor) pathway (31) and osmoreceptors (32) are known to reside outside of the blood-brain barrier, an effect of intravenous opioid antagonists on these two anatomically separate pathways (33) for AVP release is certainly tenable (26, 27) . However, since opioid antagonists are known to penetrate the blood-brain barrier readily (34) , their intravenous effect on AVP release could reside at the level of the paraventricular and supraoptic nuclei in the hypothalamus. Recent investigations (10, 11, 13) in which intracerebroventricular administrations of opiate or opioid peptides caused an increase in AVP release support this possibility and are quite compatible with the present results. As already mentioned, enkephalin-containing neurons have been demonstrated to be interspersed among AVP-and oxytocin-containing neurons in the hypothalamus, thus making the paraventricular and supraoptic nuclei a likely site of action of the opioid antagonists. Since the axons of enkephalinergic neurons terminate in the neurohypophysis, an effect of the opioid antagonists at the level of the neurohypophysis is also possible, particularly since opioid receptor binding has been found in the neurohypophysis (5) .
In summary, the present in vivo results demonstrate that two chemically dissimilar opioid antagonists impair urinary concentration in the conscious rat by diminishing the osmotic and nonosmotic release of AVP from the hypothalamo-neurohypophyseal tract. This impairment is demonstrable in the absence of differences in MAP, glomerular filtration rate, solute excretion, and the renal response to AVP.
